Bright Minds Biosciences Inc (NASDAQ:DRUG) has a beta value of 1.25 and has seen 19.47 million shares traded in the last trading session. The company, currently valued at $11.11M, closed the last trade at $2.49 per share which meant it gained $1.41 on the day or 130.58% during that session. The DRUG stock price is 4.02% off its 52-week high price of $2.39 and 62.65% above the 52-week low of $0.93. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.1 million shares traded. The 3-month trading volume is 104.46K shares.
Bright Minds Biosciences Inc (NASDAQ:DRUG) trade information
Sporting 130.58% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the DRUG stock price touched $2.49 or saw a rise of 6.39%. Year-to-date, Bright Minds Biosciences Inc shares have moved 74.13%, while the 5-day performance has seen it change 120.35%. Over the past 30 days, the shares of Bright Minds Biosciences Inc (NASDAQ:DRUG) have changed 95.29%. Short interest in the company has seen 85132.0 shares shorted with days to cover at 3.5.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bright Minds Biosciences Inc (DRUG) estimates and forecasts
The company’s shares have gained 96.06% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -137.36% over the past 5 years.
DRUG Dividends
Bright Minds Biosciences Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bright Minds Biosciences Inc (NASDAQ:DRUG)’s Major holders
Insiders own 35.48% of the company shares, while shares held by institutions stand at 4.42% with a share float percentage of 6.86%. Investors are also buoyed by the number of investors in a company, with Bright Minds Biosciences Inc having a total of 6.0 institutions that hold shares in the company.
